What is a GLP-1 receptor agonist?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals to your brain that you are full, slows the rate at which your stomach empties, and helps regulate blood sugar by stimulating insulin release. GLP-1 receptor agonists are medications that mimic this hormone — but with a much longer duration of action than the natural version, which breaks down within minutes.
The two most widely used GLP-1 medications for weight management in the UK are semaglutide (sold as Wegovy for weight loss, or Ozempic for type 2 diabetes) and tirzepatide (Mounjaro), which also activates the GIP receptor and tends to produce greater weight loss in clinical trials.
How do they produce weight loss?
The primary mechanism is appetite suppression. By activating GLP-1 receptors in the hypothalamus — the brain region that governs hunger and satiety — these medications reduce the drive to eat. Patients consistently report that food feels less compelling, portion sizes naturally decrease, and the urge to snack between meals diminishes.
Secondarily, gastric emptying slows, meaning food stays in the stomach longer and the feeling of fullness is prolonged. This is not a stimulant effect; patients do not feel jittery or artificially suppressed. Most describe it as simply not feeling hungry in the way they used to.
What weight loss can I realistically expect?
Clinical trial data is striking. The STEP 1 trial for semaglutide 2.4mg (Wegovy) showed an average body weight reduction of 14.9% over 68 weeks. The SURMOUNT-1 trial for tirzepatide 15mg (Mounjaro) showed an average reduction of 20.9% — the highest ever recorded for a pharmaceutical weight loss intervention.
In practice, results vary. Factors including starting weight, adherence to dose escalation, dietary habits, and individual metabolic response all influence outcomes. Most patients begin to notice appetite changes within the first two weeks, with meaningful weight loss typically visible by weeks 8–12.
The Open Vault
Track your progress with the Hunger Vault
EVERLean members get access to the Hunger Vault — a structured toolkit for understanding your hunger signals, tracking patterns, and knowing when appetite suppression is working as it should.
Explore The Open VaultWho is eligible for GLP-1 treatment?
In the UK, clinical guidelines support GLP-1 treatment for adults with a BMI of 30 or above, or 27.5 or above in certain ethnic groups where metabolic risk is elevated at lower BMI thresholds. Eligibility also depends on the absence of contraindicated conditions — including a personal or family history of medullary thyroid cancer, pancreatitis, or type 1 diabetes.
At EVERLean, every patient completes a structured clinical questionnaire reviewed by a prescribing doctor before any medication is issued. This is not a formality — it is the foundation of safe, effective treatment.
The Dispensary
Ready to start Wegovy or Mounjaro?
Browse our full range of GLP-1 medications with transparent per-dose pricing. All prescriptions are issued by GMC-registered doctors following a clinical assessment.
Visit The DispensaryAre GLP-1 medications safe long-term?
The long-term safety profile of semaglutide is well-established, with over a decade of data from its use in type 2 diabetes management. Tirzepatide has a shorter but rapidly growing evidence base. The most common side effects are gastrointestinal — nausea, constipation, and occasionally vomiting — and these are typically transient, peaking during dose escalation and resolving as the body adapts.
Serious adverse events are rare. Pancreatitis, gallbladder disease, and heart rate increases have been observed in a small proportion of patients and are monitored for in clinical practice. The cardiovascular benefits of significant weight loss — reduced blood pressure, improved lipid profiles, lower HbA1c — generally outweigh the risks for eligible patients.
